Tomophase

Home > News > Company news

Tomophase Corporation to Present at Massachusetts Medical Device Development Center (M2D2) Investor Showcase Event

2009-11-24 14:38:50 Tomophase Read

BURLINGTON, MA – November 24, 2009 / PRNewswire-First Call via COMTEX News Network – Tomophase Corporation announced that it presented its Optical Coherence Tomographic Imaging Systems (OCTIS™) results ‘Advanced Airway Microstructure Imaging’ during the Medical Device Investor Showcase Event on November 24, 2009 at the University of Massachusetts Medical Center in Worcester, MA. Tomophase showcased its second generation OCTIS technology.


“Our poster presentation at the Investor Showcase Event highlighted recent developments in our patented approach to opto-medical devices including significant improvements in speed and performance of our second generation system,” said Dr. Peter Norris, CEO.


Tomophase OCTIS systems address the needs in oncology and pulmonary medicine where early and minimally invasive diagnosis is key to successful treatments. The company?s initial focus will be applying its technology to the early stage diagnosis and treatment of lung cancer, the worlds leading cause of cancer death. If detected in an early stage, the 5 year survival rate of the lung cancer patients is over 85%. However, the early stage is asymptomatic and detection is primarily by chance. After the patients present with symptoms, the 5 year survival rate drops to 10-15%. Screening via CT scan may soon be accepted for high risk groups to reveal the presence of solitary pulmonary nodules (SPNs). Currently there is no means to differentiate between malignant and benign SPNs other than pulmonary biopsy, itself a risky procedure. Tomophase has patented technology which will, in conjunction with existing tools, enable the early-stage diagnosis in a non-invasive and reliable way.


About the M2D2

M2D2, the Massachusetts Medical Device Development Center, is a UMass Lowell-UMass Medical School initiative that is helping entrepreneurs move new medical device ideas from patent to production. M2D2 helps them prototype and test inventions, obtain funding and build management teams so that new medical devices will be developed in the Bay State. M2D2 was established with seed funding from the UMass President?s office and is supported by the two campuses, the Massachusetts Technology Collaborative’s John Adams Innovation Institute and the Commonwealth of Massachusetts.